A novel propellant-free inhalation drug delivery system for cardiovascular drug safety evaluation in conscious dogs

Journal of Pharmacological and Toxicological Methods

Volumn 50, Issue 2, 2004, Pages 109-119

  Markert, Michael ^a   Klumpp, Anja ^a   Trautmann, Thomas ^a   Guth, Brian ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

By inhalation; Conscious labrador dog; Long acting 2 adrenoceptor agonist; Methods; QT interval; Respimat

Indexed keywords

ALCOHOL; FORMOTEROL;

AEROSOL; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DESCENDING AORTA; DIASTOLIC BLOOD PRESSURE; DOG; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE PRESSURE; HEART RATE; IMPLANTATION; INHALER; MALE; MASK; NONHUMAN; QRS COMPLEX; QT INTERVAL; SYSTOLIC BLOOD PRESSURE; TELEMETRY; TRANSDUCER;

ADMINISTRATION, INHALATION; ANIMALS; BLOOD PRESSURE; BRONCHODILATOR AGENTS; DOGS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; ETHANOLAMINES; FEMALE; HEART RATE; MALE; NEBULIZERS AND VAPORIZERS; TELEMETRY;

CANIS FAMILIARIS;

EID: 4644244216     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2004.03.006     Document Type: Article

References (28)

1. Bartow R.A., Brogden R.N. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 55:1998;303-322
2. 2-agonist drugs. Lung Biology in Health and Disease. 139:2000;119-154
3. Bennett J.A., Tattersfield A.E. Time course and relative dose potency of systematic effects from salmeterol and salbutamol in healthy subjects. Thorax. 52:1997;458-464
4. Bremner P., Woodman K., Burgess C., Crane J., Purdie G., Pearce N., Beasley R. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. European Respiration Journal. 6:1993;204-210
5. Brodde O.E., Schuler S., Kretsch R., et al. Regional distribution of beta-adrenoceptors in the human heart: Coexistence of functional beta1 -and beta2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. Journal of Cardiovascular Pharmacology. 8:1986;1235-1245
6. Brown J.E., McLeod A.A., Shand D.L. In support of cardiac chronotropic beta2 adrenoceptors. American Journal of Cardiology. 57:1986;F11-F16
7. Carlsson L., Abrahamsson C., Andersson B., Duker G., Schiller-Lindhardt G. Proarrhythmic effects of the class III antiarrhythmic agent almokalant: Importance of infusion rate, QT dispersion and early afterdepolarisations. Cardiovascular Research. 27:1993;2186-2193
8. Clapham J.C., Hamilton T.C. Effects of BRL38227, salbutamol, and aminophylline alone and in combination, on plasma potassium and on the heart. Drug Development Research. 26:1992;157-172
9. Cazzola M., Imperatore F., Salzillo A., Di Perna F., Calderaro F., Imperatore A., Matera M.G. Cardiac effects of formoterol in patients suffering from COPD with preexisting cardiac arrhytmias and hypoxemia. Chest. 114:1998;411-415
10. Cuddihy R.G., Brownstein D.G., Raabe O.G., Kanapilly G.M. Respiratory tract deposition of inhaled polydispersed aerosols in beagle dogs. Journal of Aerosol Science. 5:1973;35-45
11. Flatt A., Crane J., Purdie G., Kwong T., Beasley R., Burgess C. The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation. Postgraduate Medical Journal. 66:1990;98-101
12. Ganderton D. Chairman's summary. Journal of Aerosol Medicine. 12(1):1999;41-42
13. Guhan A.R., Cooper S., Oborne J., Lewis S., Bennett J., Tattersfield A.E. Systemic effects of formoterol and salmeterol: A dose-response comparison in healthy subjects. Thorax. 55:2000;650-656
14. Hochrainer D., Hölz H. Comparison of cloud velocities delivered from Respimat® soft mist inhaler or MDIs. Journal of Aerosol Medicine. 14(3):2001;1-5
15. FDA Guidance for industry S7A safety pharmacology studies for human pharmaceuticals. 2001
16. Lecaillon J.B., Kaiser G., Palmisano M. Pharmacokinetics and tolerability of formoterol in health volunteers after a single high dose of Foradil dry powder inhalation via aerolizer™ European Journal of Clinical Pharmacology. 55:1999;131-139
17. Matsunaga T., Mitsui T., Harada T., Inokuma M., Murano H., Shibutani Y. QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. Journal of Pharmacological and Toxicological Methods. 38:1997;201-209
18. 2- agonist in asthma therapy. Chest. 113:1998;1095-1108
19. Newmann S.P. Use of gamma scintigraphy to evaluate the performance of new inhalers. Journal of Aerosol Medicine. 12(1):1999;25-31
20. Sarma J.S.M., Sarma R.J., Bilitsch M., Katz D. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: Reevaluation of Bazett's formula. American Journal of Cardiology. 54:1984;103-108
21. Strauss M.H., Reeves R.A., Smith D.L., et al. The role of cardiac beta-1 receptors in the hermodynamic response to a beta-2 agonist. Clinical Pharmacology Therapy. 40:1986;108-115
22. 2-agonists in the management of asthma: Recent advances and current recommendations. International Journal of Clinical Practice. 57:1998;482-486
23. Tattersfield A.E. Clinical pharmacology of long-acting-receptor agonists. Life Sciences. 52:1993;2161-2169
24. Van Noord J.A. Delivery of fenoterol via Respimat® Respiration. 67:2000;672-678
25. Vaugham Williams E.M. Cardiac electrophysiologic effects of selective adrenoceptor stimulation and their possible roles in arrhythmias. Journal of Cardiovascular Pharmacology. 7(suppl. 5):1985;61-64
26. Vincken W.J., Aumann M., Radermecker H., Slabbynck I., Stappaerts M., Demedts M., Moonen D. Comparison of pharmacodynamics, efficacy and safety of fenoterol inhaled from a novel pocket-sized inhaler and from a metered dose inhaler (MDI). European Respiratory Journal. 10(Suppl. 25):1997;239
27. 3 particles in beagle dogs, Fischer-344 rats, and CD-1 mice. American Industrial Hygiene Association Journal. 45:1984;377-381
28. Zierenberg B. Optimizing the in vitro performance of Respimat. Journal of Aerosol Medicine. 12:1999;19-24